APR 15 CRDAC

The US FDA has scheduled a Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting for Wednesday, April 15, 2015 to discuss new drug application New Drug Application 204958, cangrelor injection, submitted by The Medicines Company, for the proposed indication of reduction of thrombotic cardiovascular events including stent thrombosis (events related to blood clots in a stent, a device inserted to keep the artery open) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). PCI refers to the opening of narrowed blood vessels supplying the heart muscle by a balloon inserted through an artery puncture with or without a stent.

See the FDA Announcement